Sign in
Taking people in United StatesNo phase

Building tools to predict lung outcomes in people with pulmonary sarcoidosis

Develops models to predict how sarcoidosis progresses, using clinic visit data and blood markers.

Key facts

Who runs it
University of California, San Francisco
Where
Baltimore and Dallas, United StatesSee the 2 sites
Trial code
Registry title
Risk Indicators of Sarcoidosis Evolution-Unified Protocol
Status
Recruiting
People taking part
200 people, planned
Started
10 Jan 2023
Expected to end
30 Mar 2030
Type of study
Observational
Record updated
8 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with sarcoidosis, an illness that causes small clumps of inflamed cells, often in the lungs. The study uses clinic data and blood tests to predict how the disease will change.

Age
Over 18 years (minimum age listed as 19 Years)
Sex
All
Disease stage
Sarcoidosis confirmed by a tissue sample (biopsy), following the 1999 American Thoracic Society statement. Other causes such as beryllium disease or mycobacterial, viral or fungal infection must be ruled out.

Main reasons for not taking part

  • Not able to tolerate the study procedures, as judged by the investigator
  • Pregnant or breastfeeding
  • Other illnesses that affect blood markers, such as common variable immunodeficiency, HIV infection or autoimmune diseases
  • Other lung scarring or inflammation diseases, such as hypersensitivity pneumonitis or idiopathic pulmonary fibrosis
  • Hematocrit (Packed Cell Volume) < 25%

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Adults with a diagnosis of sarcoidosis over the age of 18
  • Case definition: we will follow the 1999 statement on sarcoidosis published by the American Thoracic Society for diagnosis which includes tissue biopsy confirmation and exclusion of alternative diagnoses including beryllium sensitization/chronic beryllium disease, mycobacterial, viral, and/or fungal infection

Who cannot take part

  • Concurrent medical diagnoses that would influence the expression of biomarkers will be considered an exclusion criterion. This includes diseases such as common variable immunodeficiency, HIV infection, or autoimmune diseases
  • Concurrent interstitial lung diseases such as hypersensitivity pneumonitis or idiopathic pulmonary fibrosis
  • Inability to tolerate study procedures as determined by the investigator
  • Pregnant or breastfeeding
  • Hematocrit (Packed Cell Volume) < 25%

Where in United States

  • University of MarylandBaltimore, United StatesContact: Wonder P Drake, MDTaking people
  • UT SouthwesternDallas, United StatesContact: Fabiola GianellaTaking people

About the trial

What the trial wants to find out

The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis
Plain-language title
Building tools to predict lung outcomes in people with pulmonary sarcoidosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Publications
Record updated
8 January 2026